indinavir sulfate - Profile

What are the generic drug sources for indinavir sulfate and what is the scope of freedom to operate?

Indinavir sulfate is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. Additional information is available in the individual branded drug profile pages.

Summary for indinavir sulfate

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for indinavir sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-006	Apr 19, 2000		DISCN	No	No
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-003	Mar 13, 1996		DISCN	Yes	No
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-005	Dec 17, 1998		DISCN	No	No
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-001	Mar 13, 1996		DISCN	Yes	No

Expired US Patents for indinavir sulfate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-003	Mar 13, 1996
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-006	Apr 19, 2000
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-006	Apr 19, 2000
Merck Sharp Dohme	CRIXIVAN	indinavir sulfate	CAPSULE;ORAL	020685-001	Mar 13, 1996

Investment Scenario and Fundamentals Analysis for Indinavir Sulfate

Last updated: February 12, 2026

Overview

Indinavir sulfate is an antiretroviral drug developed by Merck & Co. for the treatment of HIV/AIDS. It belongs to the protease inhibitor class, blocking viral replication. Despite its historical significance, market dynamics and patent status influence investment prospects.

Market Context

• The global HIV treatment market was valued at approximately USD 23.2 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 3.5% through 2030 (source: Research and Markets).
• Protease inhibitors account for roughly 30% of the market among antiretrovirals.
• Indinavir’s patent expired in 2006; generic versions entered markets primarily in developing countries, reducing potential revenue from the original formulation.

Current Patent and Regulatory Status

• No current patents protect indinavir sulfate filings by Merck due to patent expiration.
• Regulatory agencies have approved generic formulations in multiple regions.
• Regulatory barriers for bringing a new indinavir sulfate-based product are low since existing formulations are well established.

Pricing and Competition

• Original branded indinavir sulfate (marketed as Crixivan) was priced top-tier during early launch, but generics now dominate:
  • In the US, generics sell at roughly 20-30% of original branded prices.
  • In emerging markets, prices are significantly lower, shifting the competitive landscape.
• Competition stems primarily from newer classes like integrase inhibitors (e.g., dolutegravir), which are increasingly standard for HIV treatment.

Development and Commercialization Opportunities

• Extending formulations: Multiple attempts exist to develop sustained-release or fixed-dose combinations (FDCs) incorporating indinavir.
• Combination therapies: Potential for integrating indinavir sulfate into FDCs with other antiretrovirals.
• Patentably novel formulations or delivery mechanisms could provide differentiation.

Investment Considerations

• High R&D costs (>USD 50 million for a new formulation) with uncertain market uptake.
• Market saturation: Due to patent expiry, competing generics severely limit pricing power.
• Regulatory hurdles are minimal, reducing development time.
• Commercial viability depends on whether a novel, patent-protected formulation can be developed.

Financial Forecasts and Risks

Factor	Impact	Explanation
Patent exclusivity	Low future revenue potential	Patent expiry led to generics entry; minimal exclusivity.
Market share	Limited for original molecule	Generics dominate pricing and supply.
R&D investment	High; uncertain ROI	Developing a new formulation demands significant capital.
Competition	Intense, with newer therapies	Protease inhibitors face competition from integrase-based drugs.
Reimbursement trends	Favor newer therapies	Payors prefer drugs with better safety profiles and convenience.

Strategic Outlook

• For investors, the key is identifying niche opportunities, such as novel delivery methods or permanently patentable formulations.
• License or acquire rights for existing formulations with potential for reformulation.
• Focus on regions with limited access to newer drugs, like certain developing countries, where cost advantages remain significant.

Key Takeaways

• Indinavir sulfate's patent expiration limits revenue prospects in established markets.
• Market growth is driven primarily by newer drug classes; protease inhibitors decline in relevance.
• Opportunities exist in formulation innovation, but development costs and market saturation pose challenges.
• Focus on niche or underserved markets with potential for reformulation-based patents.
• Investment returns hinge on successful differentiation rather than core molecule sales.

FAQs

1. Is there ongoing research on indinavir sulfate?
   Research is limited; most activity focuses on developing new formulations or combination therapies.

2. Can new patents be secured on indinavir sulfate?
   Patents can be granted for novel formulations, delivery mechanisms, or combinations but not on the molecule itself.

3. What is the primary competitive threat to indinavir sulfate?
   The rise of integrase inhibitors and other newer antiretroviral classes.

4. Are there opportunities in emerging markets?
   Yes, where cost-effective generics dominate, but profit margins are lower.

5. What is the future outlook for indinavir sulfate as a standalone product?
   Limited, given market saturation and the shift toward newer therapies.

References

[1] Research and Markets. Global HIV Treatment Market Size & Trends. 2022.